Document Detail

Effects of infliximab therapy on biological markers of synovium activity and cartilage breakdown in patients with rheumatoid arthritis.
MedLine Citation:
PMID:  18713784     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Defining the remission criteria of rheumatoid arthritis (RA) remains a critical issue. Markers of synovium activity, urinary glucosyl-galactosyl-pyridinoline (Glc-Gal-PYD) and of cartilage destruction, urinary C-terminal crosslinking telopeptide of type II collagen (CTX-II) have been shown to reflect disease activity and joint damage progression in RA. METHODS: The prospective study cohort comprised 66 RA patients treated with infliximab and methotrexate and 76 healthy controls. Measurements of urinary Glc-Gal-PYD and CTX-II were performed at baseline and at 1 year of infliximab therapy. RESULTS: At baseline, urinary Glc-Gal-PYD and CTX-II levels were increased in patients with RA and correlated with modified Sharp scores and progression of joint damage. Patients with more progressive joint destruction had higher Glc-Gly-PYD and CTX-II baseline levels. CONCLUSION: These markers reflected bone erosion evolution and might be useful for treatment monitoring and evaluation of RA. Markers remained high even in clinical responders after infliximab, suggesting persistence of synovitis.
H Marotte; E Gineyts; P Miossec; P D Delmas
Related Documents :
2480754 - Serological abnormalities, including common idiotype pr4, in families with rheumatoid a...
22016484 - Fraction of exhaled nitric oxide in patients with acute eosinophilic pneumonia.
759244 - Juvenile-onset diabetes hla-a, -b, -c, and -dr alloantigens.
12429534 - Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status...
24557334 - Liver involvement in patients with brucellosis: results of the marmara study.
11053724 - Effect of concomitant digoxin and carvedilol therapy on mortality and morbidity in pati...
Publication Detail:
Type:  Journal Article     Date:  2008-08-19
Journal Detail:
Title:  Annals of the rheumatic diseases     Volume:  68     ISSN:  1468-2060     ISO Abbreviation:  Ann. Rheum. Dis.     Publication Date:  2009 Jul 
Date Detail:
Created Date:  2009-06-15     Completed Date:  2009-06-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372355     Medline TA:  Ann Rheum Dis     Country:  England    
Other Details:
Languages:  eng     Pagination:  1197-200     Citation Subset:  IM    
Hospices Civils de Lyon-bioMérieux Research Unit on Rheumatoid Arthritis, Hospital Edouard Herriot, Lyon, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use*
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / drug therapy*,  urine
Biological Markers / metabolism
Collagen Type II / metabolism
Cross-Linking Reagents
Disaccharides / metabolism
Methotrexate / therapeutic use*
Middle Aged
Prospective Studies
Pyridines / metabolism
Synovial Membrane / metabolism*
Treatment Outcome
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antirheumatic Agents; 0/Biological Markers; 0/Collagen Type II; 0/Cross-Linking Reagents; 0/Disaccharides; 0/Pyridines; 0/alpha-D-glucopyranosyl-(1-2)-beta-D-galactopyranosyl-O-pyridinoline; 0/infliximab; 59-05-2/Methotrexate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Deoxyspergualin in relapsing and refractory Wegener's granulomatosis.
Next Document:  Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and...